Protagonist Therapeutics, Inc.
PRTXN/A
NASDAQBiotechnology🇺🇸North America
Drugs in Pipeline
4
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
PRTX News
Catalyst Timeline
0 upcoming, 0 past
No catalysts found.
Drug Pipeline
Open-label rusfertide
Polycythemia Vera
Rusfertide
Polycythemia Vera
PTG-300
Hereditary Hemochromatosis
PN-943
Ulcerative Colitis Chronic Moderate
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Open-label rusfertide | Phase 3 | Polycythemia Vera | - | - |
Rusfertide | Phase 3 | Polycythemia Vera | - | - |
PTG-300 | Phase 2 | Hereditary Hemochromatosis | - | - |
PN-943 | Phase 2 | Ulcerative Colitis Chronic Moderate | - | - |
Polycythemia Vera
2 drugs in this indication
Ulcerative Colitis Chronic Moderate
1 drug in this indication
Hereditary Hemochromatosis
1 drug in this indication
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply